Title : Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

Pub. Date : 2015 Jan

PMID : 25481791






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 INTERPRETATION: Olaparib plus paclitaxel and carboplatin followed by maintenance monotherapy significantly improved progression-free survival versus paclitaxel plus carboplatin alone, with the greatest clinical benefit in BRCA-mutated patients, and had an acceptable and manageable tolerability profile. Paclitaxel BRCA1 DNA repair associated Homo sapiens